• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AcelRx

FDA to develop new framework for opioid analgesics following AcelRx approval

November 5, 2018 By Sarah Faulkner

AcelRx logo - updated

The FDA last week approved AcelRx‘s (NSDQ:ACRX) Dsuvia sufentanil product, noting that use of the opioid will be tightly restricted to adults experiencing acute pain in medically-supervised healthcare settings. Dsuvia is a tablet that is administered sublingually in a single-dose, pre-filled applicator. The company expects to launch its pain product in the first quarter of […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: AcelRx

AcelRx shares fall as Sen. Markey calls on FDA to reject opioid painkiller

October 22, 2018 By Sarah Faulkner

AcelRx logo - updated

Shares in AcelRx (NSDQ:ACRX) fell last week after U.S. Sen. Ed Markey (D-Mass) called on the FDA to reject the drugmaker’s opioid painkiller, Dsuvia. The senator noted that the product, which is designed for use in medically-supervised settings, consists of sufentanil – an opioid that is up to 10 times as powerful as fentanyl. “Even in […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Sublingual films, Wall Street Beat Tagged With: AcelRx

AcelRx tackles acute pain with sublingual drug-delivery tech

June 8, 2018 By Sarah Faulkner

AcelRx Pharmaceuticals

While pain medicine specialist Dr. Pamela Palmer was working on the West Coast in the early 2000’s, she noticed something peculiar was happening to patients undergoing surgery – many who survived their procedures were dying of opioid overdoses as a result of patient-controlled drug pumps. “The nurse has to program a number of parameters into […]

Filed Under: Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: AcelRx

AcelRx shares tumble after FDA rejects Dsuvia painkiller

October 12, 2017 By Sarah Faulkner

AcelRx Pharmaceuticals

Shares in AcelRx Pharmaceuticals (NSDQ:ACRX) fell more than -50% this morning after the company announced that it received a complete response letter from the FDA for its Dsuvia sufentanil sublingual tablet. The FDA told the company that it can’t approve the new drug application in its present form, saying that AcelRx needs to collect additional data […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: AcelRx

AcelRx’s pain relief drug-device combo succeeds in late-stage trial

August 1, 2017 By Sarah Faulkner

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals (NSDQ:ACRX) touted device functionality outcomes today from the Phase III trial of its Zalviso drug-device combination product. Zalviso is designed to deliver a sublingual formulation of an opioid, sufentanil, to adult patients with moderate-to-severe pain in a hospital setting using a hand-held, pre-programmed system. The device allows patients to self-administer sufentanil as often as […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: AcelRx

Anika names medtech veteran as new president | Personnel Moves – July 31, 2017

July 31, 2017 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) last week named medtech veteran Joseph Darling as president, taking over the role from CEO Charles Sherwood. The chief exec plans to stay in the corner office as he transitions the role of president to Darling. Previously, Darling worked as an executive in privately-held orthopedic companies. He has also held senior level executive […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AcelRx, Anika Therapeutics Inc., Catalent, mannkind, Merrimack Pharmaceuticals, oramedpharmaceuticals

AcelRx touts data from Dsuvia pain relief trials

April 6, 2017 By Sarah Faulkner

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals (NSDQ:ACRX) touted efficacy and safety data today for its pain reliever, Dsuvia. The company’s lead drug candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in any country. The 4 late-phase studies enrolled 480 patients total. In 2 randomized studies, enrolled patients underwent bunionectomy […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pain Management, Surgical Tagged With: AcelRx

AcelRx gains on Q4 earnings

March 3, 2017 By Sarah Faulkner

AcelRx Pharmaceuticals

Shares in AcelRx Pharmaceuticals (NSDQ:ACRX) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results. The Redwood City, Calif.-based company pared its losses to -$9.7 million, or -21¢ per share, on sales of $6.4 million for the 3 months ended Dec. 31, for bottom-line growth of 8.2% on sales growth of […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pain Management, Wall Street Beat Tagged With: AcelRx

FDA accepts AcelRx’s NDA for Dsuvia pain reliever

February 27, 2017 By Sarah Faulkner

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals (NSDQ:ACRX) said today that the FDA accepted the company’s New Drug Application for its Dsuvia pain relief therapy. The federal watchdog set a target decision date for October 12 this year. The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator to patients with moderate-to-severe […]

Filed Under: Featured, Food & Drug Administration (FDA), Pain Management, Regulatory/Compliance, Sublingual films Tagged With: AcelRx

AcelRx touts Dsuvia data for burn victims

February 13, 2017 By Sarah Faulkner

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals (NSDQ:ACRX) said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or injury. The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pain Management, Wound Care Tagged With: AcelRx

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS